このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care

2026年9月25日 更新者:CHAO-HUNG WANG, MD、Chang Gung Memorial Hospital

Integration of Metabolic Assessment on Phenylalanine Axis and Clinical Databank-based Artificial Intelligence Computation in Heart Failure: Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care

Heart failure is a complex clinical syndrome with high hospitalization rates and high mortality risks. While N-terminal-pro B-type natriuretic peptide (NT-proBNP) is widely used in clinical practice to assist in diagnosis and assessment, its ability to detect prognosis in heart failure remains insufficient. Recent scientific research has found that phenylalanine in the blood and its endogenous toxic substance phenylpyruvate are closely related to impaired energy synthesis in heart muscle cells, making them highly promising next-generation long-term biomarkers. Our research team has previously developed a "risk score" prediction model that combines phenylpyruvate levels in the blood with clinical data; this project aims to further confirm its clinical value.

Therefore, the investigators cordially invite heart failure patients who are being followed up in the cardiology outpatient clinic to have their "phenylalanine" and "phenylpyruvic acid" concentrations measured in a small amount of blood. This data, combined with clinical data, will be used to calculate a "Risk Score" to identify high-risk heart failure patients earlier.

調査の概要

状態

まだ募集していません

詳細な説明

I. Background:

Heart failure is a complex syndrome. Any abnormality in cardiac structure or function that affects ventricular congestion or ejection can lead to heart failure. Clinically, heart failure is classified into four categories based on the presence or absence of abnormal left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), heart failure with normal left ventricular ejection fraction (LVEF ≥ 50%), and heart failure with improved ejection fraction (HFimpEF) (previously LVEF ≤ 40%, followed by follow-up to LVEF > 40%). The New York Heart Association functional classification (NYHA Fc) further classifies participants into grades I through IV based on the degree of limitation in physical activity. Participants diagnosed with HFrEF who exhibit symptoms of NYHA Fc grades 2 to 4 require guideline-directed medical therapy (GDMT). However, a good assessment strategy for long-term follow-up after treatment remains lacking.

Among existing diagnostic and treatment strategies, NT-proBNP is the most widely used biomarker for diagnosis and prognostic assessment. However, its ability to identify early abnormalities of heart failure relapse, quantify metabolic abnormalities caused by heart failure, and detect endogenous toxicities caused by heart failure is still insufficient, and its assessment of heart failure prognosis is also imprecise. Elevated blood concentrations of phenylalanine and its metabolite phenylpyruvate are currently considered highly relevant to the pathophysiological mechanisms of heart failure exacerbation and can lead to the accumulation of phenylalanine and its downstream metabolite phenylpyruvate in the body fluids and tissues of heart failure patients, further worsening cardiac function. Furthermore, these metabolic disorders are closely associated with oxidative stress, mitochondrial dysfunction, and impaired energy synthesis. These alterations have been confirmed in animal models and clinical patients. They hold great potential as biomarkers for long-term monitoring by capturing early metabolic abnormalities and endogenous toxicities in heart failure.

Therefore, this study focuses on phenylalanine and phenylpyruvate metabolites to assess their correlation with patient prognosis. In another part, the investigators used the Chang Gung database for data analysis and integrated metabolite testing and clinical data into a "Risk Score" to identify high-risk patients. This aims to provide heart failure patients with more precise metabolic assessment and clinical management tools, thereby improving their quality of life and reducing disease-related mortality and hospitalization rates.

II. Objectives:

  1. To uniformly quantify phenylalanine and phenylpyruvate using high-order mass spectrometry and verify their correlation with the worsening of heart failure.
  2. To use the developed "Risk Score" in prospective, multicenter, observational validation studies (including Chang Gung Memorial Hospital, Mackay Memorial Hospital, Cheng Hsin General Hospital, and National Taiwan University Hospital) to assess its clinical predictive ability, calibration, discrimination, and cross-center generalization ability in participants with chronic outpatient heart failure.

III. Methods The investigators will enroll participants at outpatient clinic at different hospitals. Then, fasting blood (3 ml) will be collected once to get the plasma after centrifugation. Phenylpyruvate (PPA) concentration will be measured by liquid chromatography-mass spectrometry (LC-MS/MS).

Based on clinical information and the blood levels of NT-proBNP and PPA, a risk score will be calculated.

For clinical outcomes, the investigators will follow up participants' events of recurrent worsening heart failure, which will be explained in the primary and secondary outcome section.

The investigators will do statistical analysis to see the prognostic value of PPA concentrations and the risk scores.

研究の種類

観察的

入学 (推定)

800

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Chao-Hung Wang, MD, PhD
  • 電話番号:0975360604
  • メール:bearty54@gmail.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Outpatients with chronic heart failure

説明

Inclusion Criteria:

  • Adult men and women aged 18 to 85 years
  • Patients with chronic heart failure diagnosed as stage C or D in outpatient settings. Stage definitions are based on the American Heart Association Heart Failure Classification System.
  • Patients with a recorded left ventricular ejection fraction (LVEF) ≤ 40% in their medical history, but LVEF is not restricted at the time of admission to include patients with heart failure with reduced ejection fraction (HFrEF), heart failure with improved ejection fraction (HFimpEF), and those potentially progressing to heart failure with mildly reduced ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF).
  • Patients who have recently been hospitalized for acute heart failure must be discharged and have been clinically stable for at least three months before inclusion.

Exclusion Criteria:

  • Patients with other serious comorbidities that significantly impact life expectancy or survival within three months based on clinical assessment, such as terminal cancer or severe multiple organ failure.
  • Patients with New York Heart Association (NYHA) class IV and unstable clinical condition requiring frequent intravenous therapy or hospitalization.
  • Patients currently receiving maintenance hemodialysis or peritoneal dialysis.
  • Patients who are unable to complete basic follow-up, lack key clinical data, or do not consent to the use of the specimen and data.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
outpatients with chronic heart failure

Inclusion Criteria:

  • Adult men and women aged 18 to 85 years
  • Patients with chronic heart failure diagnosed as stage C or D in outpatient settings. Stage definitions are based on the American Heart Association Heart Failure Classification System.
  • Patients with a recorded left ventricular ejection fraction (LVEF) ≤ 40% in their medical history, but LVEF is not restricted at the time of admission to include patients with heart failure with reduced ejection fraction (HFrEF), heart failure with improved ejection fraction (HFimpEF), and those potentially progressing to heart failure with mildly reduced ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF).
  • Patients who have recently been hospitalized for acute heart failure must be discharged and have been clinically stable for at least three months before inclusion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recurrent worsening heart failure (HF) event burden
時間枠:within 36 months after enrollment

Recurrent worsening heart failure (HF) event burden within 36 months after enrollment. Events include:

  1. Hospitalization for worsening HF
  2. HF worsening treated at emergency or outpatient clinic
  3. intensive diuretic care event
  4. All-cause death
within 36 months after enrollment

二次結果の測定

結果測定
メジャーの説明
時間枠
Composite events
時間枠:within 36 months after enrollment
  1. First hospitalization for worsening heart failure, emergency heart failure care, or all-cause death within 36 months
  2. Number of heart failure hospitalizations, number of emergency/unexpected care visits, and total days of hospitalization within 36 months
within 36 months after enrollment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月18日

一次修了 (推定)

2030年10月31日

研究の完了 (推定)

2030年10月31日

試験登録日

最初に提出

2026年9月18日

QC基準を満たした最初の提出物

2026年9月18日

最初の投稿 (実際)

2026年9月24日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 202500252B0C6002

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する